CGEM

Cullinan Therapeutics Inc

14.92

Oct 22 • 3:59 PM ET +0.03 (0.20%)

14.92

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: CABA KYTX JANX FATE VOR ZBIO NKTX SANA IMVT IDYA

| Held by: VTI IWM XBI VXF IWN VTWO IBB DFAS FESM SCHA

Scroll to Statements

Index	RUT
Market Cap	960.17M
Enterprise Value	627.70M
Income	-204.69M
Sales	0.00M
Book/sh	4.98
Cash/sh	5.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	109
IPO	Jan 08, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.99
P/C	2.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.42
Current Ratio	8.42
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.39
EPS next Y	-2.50
EPS next Q	-0.84
EPS this Y	5.56%
EPS next Y	21.22%
EPS next 5Y	3.22%
EPS past 3/5Y	- -25.62%
Sales past 3/5Y	- -
EPS Y/Y TTM	3.56%
Sales Y/Y TTM	-
EPS Q/Q	27.00%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-1.34% -

Insider Own	24.87%
Insider Trans	-0.34%
Inst Own	88.14%
Inst Trans	6.71%
ROA	-46.30%
ROE	-50.30%
ROIC	-63.34%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.29%
SMA50	-19.85%
SMA200	-4.87%
Trades

Shs Outstand	64.35M
Shs Float	48.50M
Short Float	15.74%
Short Ratio	8.50
Short Interest	7.63M
52W High	23.19 -35.66%
52W Low	6.73 121.63%
Volatility	6.96% 6.89%
ATR (14)	1.02
RSI (14)	42.69
Beta	-0.03
Rel Volume	0.44
Avg Volume	898.07K
Volume	392,255

Perf Week	6.57%
Perf Month	-11.56%
Perf Quarter	-12.75%
Perf Half Y	15.21%
Perf YTD	44.15%
Perf Year	83.74%
Perf 3Y	70.90%
Perf 5Y	-32.82%
Perf 10Y	-
Recom	1.00
Target Price	34.58
Prev Close	14.89
Price	14.92
Change %	0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-17-26	Initiated	Citigroup	Buy	$33
Feb-02-26	Initiated	Guggenheim	Buy	$30
Aug-21-25	Resumed	H.C. Wainwright	Buy	$24
Jun-11-25	Resumed	Stifel	Buy	$22
Oct-24-24	Initiated	UBS	Buy	$30
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Show Previous Ratings

Oct-08-26 07:00AM	Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
Oct-01-26 07:30PM	New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program (GlobeNewswire) -5.34% +6.74%
Sep-24-26 03:08PM	CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December Zipalertinib Safety Worries Linger (Stocktwits) -8.48%
09:57AM	Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs (InvestorsHub)
07:00AM	Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio (GlobeNewswire)
12:00PM	Loading…
Sep-21-26 12:00PM	Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Sep-14-26 10:09AM	Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results (InvestorsHub)
07:00AM	Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer (GlobeNewswire)
Sep-10-26 01:00PM	Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer (GlobeNewswire)
Aug-13-26 08:05AM	New Taiho, Cullinan data heats up lung cancer drug battle (BioPharma Dive)
08:05AM	New Taiho, Cullian data heats up lung cancer drug battle (BioPharma Dive)
Aug-06-26 07:18AM	Cullinan Therapeutics: Q2 Earnings Snapshot (Associated Press)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-28-26 07:00AM	Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML (GlobeNewswire)
Jul-02-26 06:40PM	VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone (Exec Edge)
11:40AM	Loading…
Jun-22-26 11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge) +15.10%
Jun-10-26 07:30AM	Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases (GlobeNewswire) -8.57%
Jun-06-26 05:15AM	Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress (GlobeNewswire)
May-26-26 07:00AM	Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager (GlobeNewswire) +11.71%
May-19-26 07:00AM	Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire)
May-18-26 05:00PM	Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress (GlobeNewswire) -5.47%
08:34AM	The Biology Came First. (Business Wire)
May-07-26 07:11AM	Cullinan Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Mar-10-26 07:23AM	Cullinan Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-08-26 12:03AM	Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference (MarketBeat)
Feb-24-26 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 08:12PM	Cullinan Therapeutics Touts 2026 Defining Year as T-Cell Engager, Zipalertinib Catalysts Near (MarketBeat) +11.58%
07:17AM	TheStreet Pro Analysts Say, Its a Stock Pickers Market Here Are 4 to Consider (TipRanks)
07:00AM	Loading…
Feb-18-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-13-26 02:09AM	Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track Momentum (MarketBeat)
Feb-05-26 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-23-26 08:55AM	Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength (Zacks)
Jan-09-26 07:15AM	Cullinan Therapeutics provides corporate update, anticipated 2026 milestones (TipRanks)
Jan-08-26 07:00AM	Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones (GlobeNewswire)
Dec-15-25 11:10PM	Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates (Insider Monkey) -9.23% -5.55%
Dec-08-25 10:31AM	Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting (GlobeNewswire) +17.47%
Dec-01-25 07:00AM	Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) -5.45%
Nov-10-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting (GlobeNewswire)
Nov-06-25 07:38AM	Cullinan Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 09:11AM	Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting (GlobeNewswire) -9.82%
Oct-25-25 11:01AM	Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 (GlobeNewswire)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks)
Sep-12-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum (GlobeNewswire)
Aug-21-25 04:05PM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.78%
Aug-07-25 07:15AM	Cullinan Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -10.79%
07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 11:40PM	Cullinan Therapeutics to Present Updated Zipalertinib Data at IASLC 2025 World Conference on Lung Cancer (Insider Monkey)
Jul-22-25 07:00AM	Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) +7.85%
Jul-14-25 08:30AM	Disc Medicine Appoints Nadim Ahmed to its Board of Directors (GlobeNewswire)
Jun-05-25 07:31AM	Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal (BioPharma Dive)
Jun-04-25 04:02PM	Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases (GlobeNewswire)
Jun-01-25 08:21AM	Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology (PR Newswire)
May-29-25 07:00AM	Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +10.71%
May-22-25 05:15PM	Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 (GlobeNewswire)
May-08-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 09:55AM	Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know (Zacks)
Apr-29-25 07:00AM	Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sj gren's Disease in the United States (GlobeNewswire)
Apr-23-25 10:14AM	Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 (GlobeNewswire)
Apr-16-25 07:00AM	Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis (GlobeNewswire)
Apr-08-25 10:42AM	Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data (Seeking Alpha)
Feb-27-25 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 07:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-28-25 07:00PM	Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy (PR Newswire) +7.66%
Nov-14-24 10:01AM	Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 (GlobeNewswire)
Nov-07-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.46%
Nov-05-24 07:00AM	Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-04-24 07:00AM	Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus (GlobeNewswire) +8.44%
Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Sep 08 '26	Option Exercise	4.30	4,000	17,200	166,844	Sep 10 09:22 AM
Michaelson Jennifer	Chief Scientific Officer	Sep 08 '26	Sale	21.57	8,000	172,560	158,844	Sep 10 09:22 AM
JENNIFER MICHAELSON	Officer	Sep 08 '26	Proposed Sale	22.09	8,000	176,720		Sep 08 04:25 PM
Michaelson Jennifer	Chief Scientific Officer	Aug 13 '26	Option Exercise	4.30	30,000	129,000	192,844	Aug 14 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Aug 13 '26	Sale	20.26	30,000	607,800	162,844	Aug 14 05:00 PM
JENNIFER MICHAELSON	Officer	Aug 13 '26	Proposed Sale	19.60	30,000	588,000		Aug 13 04:33 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 06 '26	Option Exercise	4.30	4,000	17,200	170,844	Jul 07 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 06 '26	Sale	17.82	8,000	142,560	162,844	Jul 07 05:00 PM
JENNIFER MICHAELSON	Officer	Jul 06 '26	Proposed Sale	17.63	8,000	141,040		Jul 06 04:25 PM
Michaelson Jennifer	Chief Scientific Officer	May 05 '26	Option Exercise	4.30	4,000	17,200	174,844	May 06 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	May 05 '26	Sale	14.62	8,000	116,996	166,844	May 06 05:00 PM
JENNIFER MICHAELSON	Officer	May 05 '26	Proposed Sale	15.34	8,000	122,720		May 05 04:34 PM
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Option Exercise	4.30	4,000	17,200	178,844	Mar 09 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Sale	15.68	8,000	125,440	170,844	Mar 09 05:00 PM
JENNIFER MICHAELSON	Officer	Mar 05 '26	Proposed Sale	16.30	8,000	130,400		Mar 05 04:31 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 25 '26	Sale	14.14	1,780	25,169	174,844	Feb 26 05:05 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 24 '26	Sale	14.47	3,601	52,106	176,624	Feb 25 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 23 '26	Sale	13.99	1,752	24,510	180,225	Feb 25 05:00 PM
AHMED NADIM	President and CEO	Feb 24 '26	Sale	14.47	13,515	195,562	390,803	Feb 25 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 24 '26	Sale	14.47	4,582	66,302	159,968	Feb 25 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 24 '26	Sale	14.47	3,601	52,106	128,089	Feb 25 05:00 PM
JENNIFER MICHAELSON	Officer	Feb 25 '26	Proposed Sale	14.27	1,780	25,401		Feb 25 04:33 PM
Jones Jeffrey Alan	Chief Medical Officer	Feb 20 '26	Sale	13.62	4,982	67,855	164,550	Feb 23 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 20 '26	Option Exercise	4.30	8,000	34,400	189,977	Feb 23 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 20 '26	Sale	14.08	11,742	165,366	181,977	Feb 23 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Feb 20 '26	Sale	13.62	3,742	50,966	131,690	Feb 23 05:00 PM
AHMED NADIM	President and CEO	Feb 20 '26	Sale	13.62	16,381	223,109	404,318	Feb 23 05:00 PM
Fenton Mary Kay	Chief Financial Officer	Feb 20 '26	Sale	13.62	4,398	59,901	126,380	Feb 23 05:00 PM
JENNIFER MICHAELSON	Officer	Feb 23 '26	Proposed Sale	13.65	1,752	23,915		Feb 23 04:31 PM
JENNIFER MICHAELSON	Officer	Feb 20 '26	Proposed Sale	13.88	8,000	111,040		Feb 20 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Feb 12 '26	Sale	12.03	416	5,004	128,219	Feb 13 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Jan 22 '26	Sale	12.30	4,000	49,200	128,635	Jan 23 05:00 PM
JENNIFER MICHAELSON	Officer	Jan 22 '26	Proposed Sale	11.60	4,000	46,400		Jan 22 04:33 PM
AHMED NADIM	President and CEO	Dec 23 '25	Sale	10.01	9,922	99,319	420,699	Dec 29 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 19 '25	Sale	10.01	1,345	13,463	132,635	Dec 22 05:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '25	Sale	9.67	3,480	33,652	135,432	Dec 19 05:00 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '25	Sale	9.67	4,632	44,791	169,532	Dec 19 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '25	Sale	9.67	2,898	28,024	133,980	Dec 19 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 19 '25	Proposed Sale	9.98	1,345	13,423		Dec 19 04:23 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '25	Sale	12.38	2,148	26,592	137,873	Dec 16 05:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 15 '25	Sale	11.90	995	11,840	136,878	Dec 16 05:00 PM
JENNIFER MICHAELSON	Officer	Dec 15 '25	Proposed Sale	11.92	995	11,860		Dec 15 04:16 PM
Michaelson Jennifer	Chief Scientific Officer	Nov 24 '25	Sale	12.30	4,000	49,200	138,004	Nov 25 05:00 PM
JENNIFER MICHAELSON	Officer	Nov 24 '25	Proposed Sale	9.47	4,000	37,880		Nov 24 04:28 PM
Lynx1 Capital Management LP	10% Owner	Oct 28 '25	Buy	8.40	165,667	1,391,686	8,963,500	Oct 30 05:13 PM

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

PresidentMr. Nadim Ahmed M.S.

Chief Financial OfficerMs. Mary Kay Fenton CPA

M.D.Dr. Jeffrey Jones M.B.A.

Co-FounderDr. Patrick A. Baeuerle Ph.D.

Chief Scientific OfficerDr. Jennifer Michaelson Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Therapeutics Inc

Upgrade your Finviz experience